Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch
Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request.
The details of the settlement agreement remain confidential between the companies involved.
Read the full report on The Economic Times
Story file
- Section
- Health
- Topics
- Health alerts
- First reported by
- The Economic Times
- Reporter
- reuters
- Published
- Thursday, 15 October 2026, 7:21 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from The Economic Times with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
